Global Appendix Cancer Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|闌尾癌的全球市場(2020年∼2027年) Global Appendix Cancer Market - 2020-2027|
|出版日期: 2021年05月27日||內容資訊: 英文 180 Pages||
The global appendix cancer market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Appendix cancer is sometimes called appendiceal cancer. It occurs when healthy cells become abnormal and grow rapidly. These cancerous cells become a mass or tumor inside the appendix. When the tumor is malignant, it's considered cancerous. Appendix cancer is considered very rare. In the United States, there are about 1.2 cases of appendix cancer per 100,000 people each year, according to a 2015 review.
Unfortunately, because of its rarity, cases of appendix cancer are typically clustered into one group. The treatment and prognosis, however, vary greatly depending on the type of cancer and how much it has spread. Furthermore, cancer of the appendix actually manifests as several conditions, not just one disease. Young adults, people in their late teens and early twenties, can get appendix cancer, but the disease is rare in children. The global appendix cancer market is expected to grow significantly over the forecast period.
The appendix cancer market growth is driven by increasing patient assistance programs (PAPs), increasing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players, along with the increasing demand for personalized medicine.
Increase in the number of cancer cases and the rise in the geriatric population are attributing to the growth of the market
The increase in the number of appendix cancer cases and the rise in the geriatric population are the major factors that are attributing to the growth of the market, globally. In the US, it has been thought to affect about 1 or 2 people per 1 million per year. However, recent studies show that appendix cancer is becoming more common. It is more common in people between the ages of 50 and 55 years old, but can happen at any age.
The increasing incidence of appendix cancer cases is expected to drive the need for advanced cancer therapies for the effective treatment of patients. Thus, given the aforementioned factors, the market is expected to witness tremendous growth over the forecast period.
Furthermore, increase in the emergence of new technologies like biomarkers and point of care testing, inclination toward advanced less-painful and way more efficient tests from conventional tests, improved healthcare expenditure, growing awareness, and increased government support are the few more factors, which are boosting the growth of the market.
Government initiatives to increase awareness regarding severity of disease are expected to drive the growth
Government initiatives to increase awareness regarding severity of diseases are the factors anticipated to drive the appendix cancer market during the forecast period. Furthermore, rise in focus on research and development in order to improve the innovative treatment options and develop targeted therapies for appendix cancer is likely to drive the growth of the market.
Strategic developments by key players are likely to augment the appendix cancer market during the forecast period. For instance, in June 2019, Pfizer Inc. agreed to acquire Array BioPharma Inc. to boost the cancer treatment portfolio. Furthermore, the development of new diagnosis of cancer is also expected to support the market growth. In January 2020, in India, Allengers launched the ACUTOM-32 CT scanner in collaboration with Canon Medical Systems Corporation (CMSC).
Lack of well-defined classifications owing to the rarity of disease hinders the growth of the appendix cancer market
However, lack of well-defined classifications owing to the rarity of this type of cancer turns into limiting the amount of research. Thus, it restrains the growth of appendix cancer market. Also, expensive diagnostic procedures will hamper the market growth in the forecast period.
COVID-19 Impact Analysis
Due to the outbreak of the COVID-19, the market observed a significant setback in terms of growth. As the COVID-19 cases were rising, the healthcare system had shifted its focus in curbing the disease thereby resulting in the delay of diagnosis and treatment of other chronic conditions like appendix cancer.
Thus, a negative impact is expected on the appendix cancer market due to the pandemic scenario. However, in the coming years, a significant rise is expected in the diagnostic procedures related to appendix cancer.
By type , the appendix cancer market is classified into colonic-type adenocarcinoma, mucinous adenocarcinoma of appendix, goblet cell adenocarcinoma, neuroendocrine carcinoma, others.
Mucinous adenocarcinoma of appendix segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Mucinous adenocarcinoma of the appendix appears to be a biologically and histologically distinct entity from colorectal cancer and from colonic-type adenocarcinoma of the appendix. The mean age at presentation is 60 years and there is no clear predilection. There are no known risk factors for this disease. It is broadly classified histologically as low or high grade, and this distinction is greatly important for determining prognosis and treatment. The second most common type of appendix cancer, mucinous adenocarcinomas begin in the appendix and produce mucin, a jelly-like substance that tends to spread cancerous cells to other parts of the body. These tumors are often discovered after they have spread (metastasized) to the peritoneum (the lining of the abdominal cavity).
Mucinous adenocarcinoma of appendix are generally first seen as a thickened, plaque-like white mucous membrane, according to the National Cancer Institute. They often spread easily through the soft tissue where they occur.
Colonic-type adenocarcinoma has the second largest share in the segment. Patients with colonic-type adenocarcinoma of the appendix most often present with incidentally identified lesions following appendectomy for appendicitis or other indication, and will have pathologic T-stage information immediately available. Tis tumors resected with negative margins can be managed with appendectomy alone. T1 tumors with favorable characteristics are thought of like malignant polyps. Appendectomy alone may be sufficient if these lesions are grade 1 or 2, have no angiolymphatic invasion, and have negative resection margins. All patients should undergo complete colonoscopy to evaluate for synchronous colorectal lesions.
On the basis of treatment, the the appendix cancer market is classified into Surgery (Appendectomy, Hemicolectomy, Others), Chemotherapy (Local/Intraperitoneal Chemotherapy, Systemic Chemotherapy), Radiation therapy and Others.
The surgery segment are expected to dominate the appendix cancer market during the forecast period
The first line of treatment for appendix cancer is surgery it is used to remove the cancerous glandular tissue and some surrounding tissue. If possible, minimally invasive surgical procedures may be used to help reduce healing time and the risk of post-surgical infection. An appendectomy is the surgical removal of the appendix. It's a common emergency surgery that's performed to treat appendicitis, an inflammatory condition of the appendix.
Due to the structure of the appendix, it is easy for tumor or cancer cells to break through the wall and spread in the abdominal cavity. Consequently, most appendiceal cancers, even the less aggressive ones, tend to present at an advanced stage with peritoneal carcinomatosis. Thus it is necessary to do surgery. This factor will drive the segment growth in the forecast period.
North America region holds the largest market share global appendix cancer market
North America is expected to dominate the global appendix cancer market. Significant research and development, well established healthcare infrastructure, and early adoption of advanced therapies are the key factors anticipated to drive the appendix cancer market in the region. As per an article published in the Clinics in Colon and Rectal Surgery in 2015, estimated 1.2 per 100,000 cases of appendix cancer are found each year in the U.S.
In addition, U.S. and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. Additionally, Mexico is a developing nation with the benefit of being neighbor to the US. This allows many companies to penetrate in Mexico as well. This helps the growth in the region.
On the other hand, Asia Pacific expected to hold significant share of the market. The market in the region is expected to grow at a rapid pace during the forecast period. Surge in number of geriatric population and growing awareness among population are the key factors leading to drive the appendix cancer market in the region.
The appendix cancer market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson and Company, Novartis AG, GE, AstraZeneca, and Boehringer Ingelheim International GmbH among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the appendix cancer market globally.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
Key Development: In June 2019, Pfizer Inc. and Array Biopharma Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. This will expands Pfizer's pipeline with multiple high-potential targeted investigational cancer therapies and adds a large portfolio of royalty-generating out-licensed medicines
The global appendix cancer market report would provide an access to an approx. 69 market data table, 65 figures and 200 pages.
LIST NOT EXHAUSTIVE